Recent advances in gene modified immune cells and oncolytic virus for cancer immunotherapy

7,358
Total Downloads
23k
Total Views and Downloads

Articles

EDITORIAL

Published on 04 Jul 2024

Editorial: Recent advances in gene modified immune cells and oncolytic virus for cancer immunotherapy

Cunzhong Yuan
Yao Wang
Zong Sheng Guo

doi 10.3389/fimmu.2024.1454183

981 views

ORIGINAL RESEARCH

Published on 21 May 2024

shRNA-mediated gene silencing of HDAC11 empowers CAR-T cells against prostate cancer

Hongmei Zhang
Jie Yao
Iqra Ajmal
Muhammad Asad Farooq
Wenzheng Jiang

doi 10.3389/fimmu.2024.1369406

1,450 views
1 citation

ORIGINAL RESEARCH

Published on 25 Apr 2024

Targeting PD-L1 in solid cancer with myeloid cells expressing a CAR-like immune receptor

Kayla Myers Chen
Daniel Grun
Brian Gautier
Shivaprasad Venkatesha
Michael Maddox
Ai-Hong Zhang
Peter Andersen

doi 10.3389/fimmu.2024.1380065

1,562 views

REVIEW

Published on 13 Mar 2024

Recent progress in combination therapy of oncolytic vaccinia virus

Seyedeh Nasim Mirbahari
Miles Da Silva
Abril Ixchel Muñoz Zúñiga
Nika Kooshki Zamani
Gabriel St-Laurent
Mehdi Totonchi
Taha Azad

doi 10.3389/fimmu.2024.1272351

2,900 views
2 citations

ORIGINAL RESEARCH

Published on 22 Jan 2024

TCR-transgenic T cells and YB-1-based oncolytic virotherapy improve survival in a preclinical Ewing sarcoma xenograft mouse model

Sebastian J. Schober
Melanie Thiede
Hendrik Gassmann
Anna Josefine von Ofen
Pia Knoch
Jennifer Eck
Carolin Prexler
Corazon Kordass-Wally
Julia Hauer
2 more
Uwe Thiel

doi 10.3389/fimmu.2024.1330868

1,604 views
1 citation

REVIEW

Published on 15 Dec 2023

Oncolytic virotherapy in cancer treatment: challenges and optimization prospects

Lingjuan Chen
Mengsi Zuo
Qin Zhou
Yang Wang

doi 10.3389/fimmu.2023.1308890

4,951 views
17 citations

REVIEW

Published on 24 Nov 2023

The capability of heterogeneous γδ T cells in cancer treatment

Wenyi Yan
Louisa S. Chard Dunmall
Nicholas R. Lemoine
Yaohe Wang
Yafeng Wang
Pengju Wang

doi 10.3389/fimmu.2023.1285801

2,749 views

ORIGINAL RESEARCH

Published on 31 Oct 2023

A phase I oncolytic virus trial with vesicular stomatitis virus expressing human interferon beta and tyrosinase related protein 1 administered intratumorally and intravenously in uveal melanoma: safety, efficacy, and T cell responses

Katherine E. R. Smith
Kah-Whye Peng
Jose S. Pulido
Adam J. Weisbrod
Carrie A. Strand
Jacob B. Allred
Alysha N. Newsom
Lianwen Zhang
Nandakumar Packiriswamy
13 more
Matthew S. Block

doi 10.3389/fimmu.2023.1279387

2,586 views
4 citations

Share on

Frontiers in Immunology

Cancer Immunity and Immunotherapy

Participating Journals

Frontiers in Oncology
- Cancer Immunity and Immunotherapy
- 3.5 impact factor
- 6.2 citescore

Impact

23kTopic views
15kArticle views
7,358Article downloads

View impact

Submit your idea

Articles

Editorial: Recent advances in gene modified immune cells and oncolytic virus for cancer immunotherapy

shRNA-mediated gene silencing of HDAC11 empowers CAR-T cells against prostate cancer

Targeting PD-L1 in solid cancer with myeloid cells expressing a CAR-like immune receptor

Recent progress in combination therapy of oncolytic vaccinia virus

TCR-transgenic T cells and YB-1-based oncolytic virotherapy improve survival in a preclinical Ewing sarcoma xenograft mouse model

Oncolytic virotherapy in cancer treatment: challenges and optimization prospects

The capability of heterogeneous γδ T cells in cancer treatment

A phase I oncolytic virus trial with vesicular stomatitis virus expressing human interferon beta and tyrosinase related protein 1 administered intratumorally and intravenously in uveal melanoma: safety, efficacy, and T cell responses

Frontiers in Immunology

Participating Journals

Impact